Market Cap 456.10B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.19
Forward PE 18.70
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 3,224,800
Avg Vol 6,863,834
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 21%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Gebinator
Gebinator Aug. 29 at 3:08 PM
$SLS G' Morning Longs 🌞 Apologies for kinda botching last evening's poll -- my bad -- unfortunately, consuming too much wobbly juice did play into the matter ... 😣 While the poll 👇 list of choices is in alphabetical order, as @Dollarking has indicated, $ABBV shouldn't be counted out. Point well-taken, only thing is @Stocktwits allows only four choices. To meet this challenge, another new poll could later include $ABBV as a distinct choice (replacing $LLY) OR aggravated with $LLY - represented as the 'dark horse' choice candidates from previous poll. In the meantime, for what it's worth, do consider the current choices, as listed 👇 Of these four, which will it be?
2 · Reply
tr3ndo
tr3ndo Aug. 29 at 5:34 AM
$ABBV a seller zone formed, a local maximum was confirmed, and a downward correction is developing on the daily chart around $259. Price is reacting from the recent highs. AI Detective currently assigns a 47% probability to a local minimum being confirmed next. Waiting for price to confirm its next direction.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 29 at 12:10 AM
🔔 IF YOU’RE SERIOUS ABOUT TRADING, TAP IN. 💎 I’ve been sharing some of my best setups inside my Telegram community — trades and market plays that I don’t always post here on Stocktwits. 📲🔥 📈 THIS WEEK’S RESULTS: $ABBV PUTS — +246% 💎 $DE CALLS — +234% 💎 $MSFT CALLS — +190% 💎 $DE CALLS — +182% 💎 $BE CALLS — +141% 💎 👑 2 × 230%+ GAINERS 👑 5 × 100%+ GAINERS I’m not here to chase every move. I’m looking for the setups that make sense and getting positioned early. If you want to follow along, the Telegram link is in my bio. 📲🔥 STAY LOCKED IN. 👀💎
0 · Reply
Alphatrades09
Alphatrades09 Aug. 28 at 9:59 PM
🔔 THIS IS YOUR CHANCE TO JOIN MY TELEGRAM COMMUNITY! 💎 I post exclusive trade ideas and setups there that I don’t post here on Stocktwits. 📲🔥 Link is in my bio. 🔥 HIGHLIGHTS FROM THIS WEEK: $ABBV PUTS — 246% GAINER 💎 $DE CALLS — 234% GAINER 💎 $MSFT CALLS — 190% GAINER 💎 $DE CALLS — 182% GAINER 💎 $BE CALLS — 141% GAINER 💎 2 × 230%+ GAINERS 👑 5 × 100%+ GAINERS 👑 The opportunities are there—you just have to stay locked in. 👀 Telegram link in my bio. 📲🔥
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 9:06 PM
$SLS An All pooled MOS Tells the entire story - if you're $ABBV /$RHHBY and $BMY the Drug Companies that own the BAT Drugs. "They’re wrong that this means zero information: pooled counts identify pooled survival, and pooled survival plus a BAT prior constrains the HR. " IDMC Unblinded Actual Phase 3 MOS and IR Data from the Interim ... The Share Price nearly Doubled, the MCap Tripled in 3 days... SLS ran an offering - they 13m on the balance sheet - and the Co Market Cap Tripled ... in the three days after the IDMC unblinded the data. MOS was Not Yet Reached and Greater than > 13.5 months - at the time, with 13 months of Median Follow up 1 - 33 months - this was 20 months ago.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 28 at 8:33 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $3.60 🤑 246% GAINER!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 8:21 PM
$SLS $MRK $MRNA YOU NEVER HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL... Just checking -- Does Everyone KNOW AZA+VEN -BAT for the SLS Phase 3 Control Arm Patients FAILED 3 large Phase 3 Trials. - BAT for the SLS P3 Control ARM Failed 3 Large Phase 3 Trials Conducted by $ABBV While we are seeing Miraculous ALL POOLED Survival - BAT - FAILED the VIALE-M CR1 First Remission AML Maintenance Trial VIALE-T Post Transplant AML Maintenance Trial ABBV stated poor accrual/enrollment in the CR1 Maintenance trial as a reason for the FAILURE --- YOU NEVE HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL...
0 · Reply
Alphatrades09
Alphatrades09 Aug. 28 at 7:45 PM
$ABBV $3.60 here.🔥 +246% GAINER. 👑🚀
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:19 PM
$SLS $MRK $MRNA $ABBV Investment Opportunity of a Lifetime for Anyone Investing in SLS ahead of the Imminent Phase 3 Trial Results. • 15X • 20X ROI any day now.
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 28 at 7:13 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $3.60 246% GAINER! TURN MY POST NOTIFICATIONS ON! 🔔
0 · Reply
Latest News on ABBV
AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 2 days ago

AbbVie submits Skyrizi application to the EMA


AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 12 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo


AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 19 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI


AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 24 days ago

AbbVie upgraded to Buy from Hold at Erste Group


AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 25 days ago

AbbVie price target raised to $288 from $261 at Guggenheim


AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 26 days ago

AbbVie price target raised to $290 from $282 at Canaccord


AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 4 weeks ago

AbbVie says ‘quite pleased’ with Skyrizi momentum


AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 4 weeks ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84


AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 4 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend


Gebinator
Gebinator Aug. 29 at 3:08 PM
$SLS G' Morning Longs 🌞 Apologies for kinda botching last evening's poll -- my bad -- unfortunately, consuming too much wobbly juice did play into the matter ... 😣 While the poll 👇 list of choices is in alphabetical order, as @Dollarking has indicated, $ABBV shouldn't be counted out. Point well-taken, only thing is @Stocktwits allows only four choices. To meet this challenge, another new poll could later include $ABBV as a distinct choice (replacing $LLY) OR aggravated with $LLY - represented as the 'dark horse' choice candidates from previous poll. In the meantime, for what it's worth, do consider the current choices, as listed 👇 Of these four, which will it be?
2 · Reply
tr3ndo
tr3ndo Aug. 29 at 5:34 AM
$ABBV a seller zone formed, a local maximum was confirmed, and a downward correction is developing on the daily chart around $259. Price is reacting from the recent highs. AI Detective currently assigns a 47% probability to a local minimum being confirmed next. Waiting for price to confirm its next direction.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 29 at 12:10 AM
🔔 IF YOU’RE SERIOUS ABOUT TRADING, TAP IN. 💎 I’ve been sharing some of my best setups inside my Telegram community — trades and market plays that I don’t always post here on Stocktwits. 📲🔥 📈 THIS WEEK’S RESULTS: $ABBV PUTS — +246% 💎 $DE CALLS — +234% 💎 $MSFT CALLS — +190% 💎 $DE CALLS — +182% 💎 $BE CALLS — +141% 💎 👑 2 × 230%+ GAINERS 👑 5 × 100%+ GAINERS I’m not here to chase every move. I’m looking for the setups that make sense and getting positioned early. If you want to follow along, the Telegram link is in my bio. 📲🔥 STAY LOCKED IN. 👀💎
0 · Reply
Alphatrades09
Alphatrades09 Aug. 28 at 9:59 PM
🔔 THIS IS YOUR CHANCE TO JOIN MY TELEGRAM COMMUNITY! 💎 I post exclusive trade ideas and setups there that I don’t post here on Stocktwits. 📲🔥 Link is in my bio. 🔥 HIGHLIGHTS FROM THIS WEEK: $ABBV PUTS — 246% GAINER 💎 $DE CALLS — 234% GAINER 💎 $MSFT CALLS — 190% GAINER 💎 $DE CALLS — 182% GAINER 💎 $BE CALLS — 141% GAINER 💎 2 × 230%+ GAINERS 👑 5 × 100%+ GAINERS 👑 The opportunities are there—you just have to stay locked in. 👀 Telegram link in my bio. 📲🔥
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 9:06 PM
$SLS An All pooled MOS Tells the entire story - if you're $ABBV /$RHHBY and $BMY the Drug Companies that own the BAT Drugs. "They’re wrong that this means zero information: pooled counts identify pooled survival, and pooled survival plus a BAT prior constrains the HR. " IDMC Unblinded Actual Phase 3 MOS and IR Data from the Interim ... The Share Price nearly Doubled, the MCap Tripled in 3 days... SLS ran an offering - they 13m on the balance sheet - and the Co Market Cap Tripled ... in the three days after the IDMC unblinded the data. MOS was Not Yet Reached and Greater than > 13.5 months - at the time, with 13 months of Median Follow up 1 - 33 months - this was 20 months ago.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 28 at 8:33 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $3.60 🤑 246% GAINER!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 8:21 PM
$SLS $MRK $MRNA YOU NEVER HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL... Just checking -- Does Everyone KNOW AZA+VEN -BAT for the SLS Phase 3 Control Arm Patients FAILED 3 large Phase 3 Trials. - BAT for the SLS P3 Control ARM Failed 3 Large Phase 3 Trials Conducted by $ABBV While we are seeing Miraculous ALL POOLED Survival - BAT - FAILED the VIALE-M CR1 First Remission AML Maintenance Trial VIALE-T Post Transplant AML Maintenance Trial ABBV stated poor accrual/enrollment in the CR1 Maintenance trial as a reason for the FAILURE --- YOU NEVE HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL...
0 · Reply
Alphatrades09
Alphatrades09 Aug. 28 at 7:45 PM
$ABBV $3.60 here.🔥 +246% GAINER. 👑🚀
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:19 PM
$SLS $MRK $MRNA $ABBV Investment Opportunity of a Lifetime for Anyone Investing in SLS ahead of the Imminent Phase 3 Trial Results. • 15X • 20X ROI any day now.
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 28 at 7:13 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $3.60 246% GAINER! TURN MY POST NOTIFICATIONS ON! 🔔
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:12 PM
$SLS $MRK $MRNA $ABBV Your future self will thank you.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:07 PM
$SLS $MRK $MRNA $ABBV Why Did the VIALE-M Phase 3 Trial for AML First Remission Patients Fail? Why DID ABBV have difficulty ENROLLING PATIENTS in the AML Maintenance Trial? Why are We SEEING MIRACULOUS Survival in the SLS Phase 3 AML Remission Maintenance Trial - when BAT for CONTROL Patients FAILED 2 Phase 3 AML Remission Trials?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 7:01 PM
$SLS $MRK $MRNA YOU NEVE HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL... Just checking -- Does Everyone KNOW AZA+VEN BAT for the SLS Phase 3 Control Arm Patients FAILED -the BAT for the SLS P3 Control ARM Failed 3 Large Phase 3 Trials Conducted by $ABBV While we are seeing Miraculous ALL POOLED Survival - BAT - FAILED the VIALE-M CR1 First Remission AML Maintenance Trial VIALE-T Post Transplant AML Maintenance Trial ABBV stated poor accrual/enrollment in the CR1 Maintenance trial as a reason for the FAILURE --- YOU NEVE HAVE A PROBLEM ENROLLING A TRIAL WHERE PATIENTS ARE DOING WELL...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 6:57 PM
$SLS $MRK $MRNA $ABBV Gps Phase 2 Trial MOS of 67.6 months for First Remission Non-transplant setting GPS Median OS was not reached and was Greater than > 67.6 months -Vs - 24.7 months w SOC - Onureg. VIALE-M P3 Aza (onureg) +VEN Conducted by $ABBV FAILED Onureg + VEN Results were worse than Onureg Alone Due to Toxicity Direct Head to Head GPS vs BAT in First Remission Comparable: GPS MOS not Reached > 67.6 months vs BAT 19* really 17.3 months TT vs duration of remission, Gps measure. Relapse and Survival Data First Remission 19 month MOS for BAT
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 2:44 PM
$ABBV $AZN $JNJ $PFE $SLS Merger Monday’s. Biotech Contrarian Indicators flashing big time today. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 2:17 PM
$SLS $ABBV Do u think abbv bmy know exactly how thier drugs. BAT - for the SLS p3, perform? idmc unblinded data told them Gps is Golden.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 2:05 PM
$SLS $ABBV A Key Note: GPs Efficacy in preventing Relapse, and extending Survival in ALL Prior trials, is correlated w Immune Response -- Gps Specific WT1 Immune Response equals - Extended Survival. • the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM Analysis --- back in Jan 2025 -- since then, SLS has been on Fleak -All metrics Up Bigly ... • Gps elicited IR in 80% of tested P3 Patients ... Go back through my posts and see the correlation -- if you like money. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 2:03 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 1:41 PM
$SLS Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 28 at 1:25 PM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on Aza+VEN, the BAT for the SLS P3 Control ARM ? • while we are seeing miraculous extended survival in the SLS p3? $ABBV Claims they Could NOT ENROLL patients on Aza+VEN. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant. I’ve been here a long time if your interested in Money scroll my posts
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM
$ABBV $AZN $JNJ $PFE $SLS All the Repositioners, traders will be left on the sidelines when the T1 halt hits. Shorts are burying themselves deeper and deeper before liquidation 🔥 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 28 at 12:13 PM
$SLS $JNJ $PFE $ABBV $AZN Every passing day starting to look like Data+Deal coming in Consecutive order. ✌️🙏❤️‍🩹
0 · Reply